Figure 1.
Pre–CAR-T diagnostic biopsy, CD30CAR-T expansion, and detection of homeostatic cytokines. Hematoxylin and eosin stain (A; scale bar, 100 μm) and CD30 antibody stain of the tumor biopsy before CAR T-cell therapy (B; scale bar, 200 μm). (C) Detection of CD30 CAR T-cell molecular signals by quantitative polymerase chain reaction (qPCR) and of the indicated cytokines over the course of the first 6 weeks after infusion. The star indicates evaluation of the listed parameters during the CRS event. (D) Detection of IL-2, IL-7, and IL-15 in the plasma and lymphocyte counts over the course of the first 6 weeks after infusion. ALC, absolute lymphocyte count; CRP, C-reactive protein; DDU, D-dimer unit; IFNg, interferon-γ; TNFa, tumor necrosis factor-α.

Pre–CAR-T diagnostic biopsy, CD30CAR-T expansion, and detection of homeostatic cytokines. Hematoxylin and eosin stain (A; scale bar, 100 μm) and CD30 antibody stain of the tumor biopsy before CAR T-cell therapy (B; scale bar, 200 μm). (C) Detection of CD30 CAR T-cell molecular signals by quantitative polymerase chain reaction (qPCR) and of the indicated cytokines over the course of the first 6 weeks after infusion. The star indicates evaluation of the listed parameters during the CRS event. (D) Detection of IL-2, IL-7, and IL-15 in the plasma and lymphocyte counts over the course of the first 6 weeks after infusion. ALC, absolute lymphocyte count; CRP, C-reactive protein; DDU, D-dimer unit; IFNg, interferon-γ; TNFa, tumor necrosis factor-α.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal